One‐year outcomes of supersaturated oxygen therapy in acute anterior myocardial infarction: The IC‐HOT study

BACKGROUND: Supersaturated oxygen (SSO(2)) has recently been approved by the U.S. Food and Drug Administration for administration after primary percutaneous coronary intervention (pPCI) in patients with anterior ST‐segment elevation myocardial infarction (STEMI) based on its demonstration of infarct...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shmuel, David, Shukri W., Khan, Zubair A., Metzger, D. Christopher, Wasserman, Hal S., Lotfi, Amir S., Hanson, Ivan D., Dixon, Simon R., LaLonde, Thomas A., Généreux, Philippe, Ozan, M. Ozgu, Maehara, Akiko, Stone, Gregg W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Coronary Artery Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246818/
https://www.ncbi.nlm.nih.gov/pubmed/32649037
http://dx.doi.org/10.1002/ccd.29090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246818/
https://www.ncbi.nlm.nih.gov/pubmed/32649037
http://dx.doi.org/10.1002/ccd.29090

Ejemplares similares